STAT+: Pharmalittle: EMA urges revoking authorization for Novartis sickle cell drug; U.K. tries to placate pharma execs
And so, another working week will soon draw to a close. Not a moment too…
Category: STAT+
Opinion: STAT+: An overlooked way to make participants in clinical trials look more like America
A recent report from the National Academies of Sciences, Engineering and Medicine (of which one…
STAT+: U.K. unveils $800 million package to bolster life sciences amid concern over biopharma investments
LONDON — The U.K. government on Thursday unveiled an $800 million package to bolster the…
STAT+: Bristol drug reduces reliance on transfusions for people with chronic blood disorder
In a study reported Thursday, a medicine from Bristol Myers Squibb nearly doubled the treatment…
STAT+: Gilead and Teva defend antitrust claims that prices for HIV medicines were unfairly kept high
Amid concern that HIV prevention pills are not being widely taken by those at highest…
STAT+: Illumina shareholders elect one Icahn ally to board, as company holds off broader challenge
Shareholders in the DNA-sequencing firm Illumina on Thursday voted to replace the company’s chairman with…
STAT+: Pharmalittle: FDA approvals will stop if U.S. defaults on its debts; DEA failed to punish wholesaler blamed in opioid crisis
Oh, what a beautiful morning. Yes, this is a cliché, but the saying is apt,…
STAT+: With Fat Joe concerts and Super Bowl ads, a cadre of billionaires is mounting an unorthodox campaign against hospitals
WASHINGTON — At a waterfront concert in one of this city’s swankiest neighborhoods, rappers Busta…
STAT+: Matt Eyles, CEO of America’s Health Insurance Plans, to depart
Matt Eyles, CEO of America’s Health Insurance Plans, is leaving by this October, the lobbying…
STAT+: Boston Scientific cancels $230 million deal to buy Korean device company
Boston Scientific is scrapping its $230 million plan to buy a majority stake in M.I….
STAT+: Annexon’s trial of an eye disease drug missed by a mile. The company saw a bull’s eye
Annexon Biosciences said Wednesday that its experimental treatment for an eye disease called geographic atrophy…
STAT+: Immunotherapy turned brain cancers from ‘cold’ to ‘hot’ in mouse study, as clinical trials advance
LONDON — The promise of immunotherapies to treat cancer has yet to reach brain tumors….
STAT+: Congress took on high drug prices in Medicare. Now Biden wants to take it to Medicaid
WASHINGTON — The Biden administration wants to help states control Medicaid prescription drug costs by…
STAT+: Addiction treatment center founder indicted in sprawling fraud scheme
Over the last few years, Daniel Cleggett Jr. appeared to be living a charmed life….
STAT+: Pharmalittle: Biden administration proposes yearly audit for costliest Medicaid drugs; few at high risk of HIV take prevention pills
Top of the morning to you. The middle of the week is upon us and,…
STAT+: FDA delays decision on Sarepta’s gene therapy for Duchenne muscular dystrophy
The Food and Drug Administration is delaying by one month a decision on the approval…
STAT+: Battle for the soul of Illumina is also a referendum on its CEO
On Thursday Illumina, the largest and most important maker of DNA sequencing technology, whose innovations…
STAT+: Congress highlighted a chemo drug’s price to blast PBMs — but it’s not a PBM issue
WASHINGTON — Congress blasted drug middlemen at a hearing Tuesday, with multiple lawmakers pointing to…
STAT+: Learning to treat long COVID could help those struggling with chronic fatigue syndrome, too
CONCORD, N.H. — Veronica Dane had always been active, from playing soccer as a kid…
STAT+: Pharmalittle: Pfizer and Novo disclose upbeat data on oral weight loss drugs; PBM trade group blasts House committee over hearing
Rise and shine, another busy day is on the way. We can tell because the…
STAT+: Achieve Life Sciences drug helps smokers quit in trial but would face stiff competition if approved
Seattle biotech Achieve Life Sciences on Tuesday announced an experimental drug meant to help people…
STAT+: Biotech launches with $300 million, joint venture to expedite RNA drug development
Biotech venture capital may be pacing at a six-year low, but one startup just managed…
.jpg)
STAT+: Seagen criticized by shareholder advisory firm for ‘problematic’ executive compensation ahead of Pfizer acquisition
As Seagen prepares to be acquired by Pfizer, an investor advisory firm is raising concerns…
Novo says oral version of Ozempic leads to 15% weight loss
An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic…
STAT+: Pharmalittle: Many employer health plans won’t pay for obesity drugs; FDA panel rejects Intercept NASH drug
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: In early trial, drug appears to reduce harmful protein buildup in heart
An early-stage drug for a heart disease called ATTR-CM showed potential to reverse disease progression,…
STAT+: In its first tough test, CRISPR epigenome editing cuts cholesterol levels in monkeys
A defanged form of CRISPR, which doesn’t slice or nick DNA, but rather alters the…
STAT+: FDA advisers vote against approving Intercept’s NASH drug
A panel of expert advisers to the Food and Drug Administration voted Friday against approving…
STAT+: FDA approves first treatment for skin condition that causes persistent wounds, a redosable gene therapy
The Food and Drug Administration on Friday approved the first treatment for a devastating condition…
STAT+: Novo Nordisk pauses ads for weight loss drug Wegovy as it struggles to meet demand
Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep…
STAT+: FDA official offers insights into whether gene therapy makers could use common manufacturing process
WASHINGTON — A Food and Drug Administration official provided some insights this week into the…
STAT+: Pear Therapeutics sold for parts at $6 million auction
Four different companies agreed to buy the assets of Pear Therapeutics at auction on Thursday…
STAT+: Pharmalittle: AstraZeneca plans to ‘love’ China’s Communist Party; U.S. Supreme Court rules against Amgen in patent case
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Supreme Court rules against Amgen in closely watched case over scope of patent claims
In a case that had the pharmaceutical industry on edge, the U.S. Supreme Court upheld…
STAT+: New Biden science agency ARPA-H launches first program, targeting bone regrowth
WASHINGTON — A multibillion-dollar science agency tasked with slashing through research bureaucracy will start its…
STAT+: Pharmalittle: Appellate judges appear skeptical of FDA decisions on abortion pill; FTC widens probe into PBMs
Top of the morning to you, and a fine one it is. Once again, crystal…
STAT+: In Belgium, a native son returns to resurrect the drugmaker Galapagos — and ‘to get the trust back’
There is, according to Wall Street, no worse investment in biotech than Galapagos NV. The…
STAT+: FTC widens probe into pharmacy benefit managers to include group purchasing organizations
The Federal Trade Commission is widening its probe into pharmacy benefit managers and their impact…
.jpg)
STAT+: House panel takes first steps toward reining in hospitals with ‘site-neutral’ changes
WASHINGTON — A key House panel on Wednesday advanced several health care bills on Wednesday,…
STAT+: Could an upcoming Supreme Court case make the FDA slower?
WASHINGTON — The Food and Drug Administration could take longer to write regulations and make…
STAT+: CVS Health to close clinical trial unit two years after launch
WOONSOCKET, R.I. — Two years after its launch, CVS Health is planning to close down…
STAT+: Pharmalittle: FTC suit over Amgen spotlights ‘bundling’ deals with insurers; FDA staff says Pfizer RSV vaccine is effective
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: PTC Therapeutics’s PKU drug succeeds in trial, but bigger hurdles for company are ahead
Biotech firm PTC Therapeutics said Wednesday that its drug for phenylketonuria, or PKU, met its…
STAT+: A new startup looks to turn the workhorse of gene therapy against cancer
In 1980, Life and Time magazines introduced America to a new cancer wonder drug: interferon,…
STAT+: Biotech and pharma execs wrestle with the ‘nightmare’ of developing digital biomarkers
TARRYTOWN, N.Y. — As post-lunch drowsiness settled on an auditorium full of leaders from the…
STAT+: FTC move to block the Amgen-Horizon deal highlights concerns over negotiations with insurers
In an unexpected move, the U.S. Federal Trade Commission on Tuesday filed a lawsuit to…
STAT+: AI leaders issue a plea to Congress: Regulate us, and quickly
During an extraordinary hearing Tuesday, members of a Senate subcommittee called for aggressive regulation of…
STAT+: FTC files lawsuit to block Amgen’s purchase of Horizon Therapeutics
The Federal Trade Commission on Tuesday sued to block Amgen’s $27.8 billion acquisition of Horizon…
STAT+: Pharmalittle: FTC may sue to block Amgen deal for Horizon; Supreme Court declines Teva appeal on skinny labeling
Oh, what a beautiful morning! Pardon the cliché, but crystal clear blue skies and deliciously…
STAT+: General Catalyst, Andreessen Horowitz bet on large language models for health care
OAKLAND, Calif. — In a rare partnership, heavyweight tech venture firms General Catalyst and Andreessen…